Pan-immune-inflammation value is associated with poor prognosis in patients undergoing peritoneal dialysis

Immune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study, we aimed to evaluate the relationship between a novel comprehensive biomarker, the pan-immune-inflammation value (PIV), and the prognosis of patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Renal failure Ročník 45; číslo 1; s. 2158103
Hlavní autoři: Zhang, Fengping, Li, Luohua, Wu, Xianfeng, Wen, Yueqiang, Zhan, Xiaojiang, Peng, Fenfen, Wang, Xiaoyang, Zhou, Qian, Feng, Xiaoran
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Taylor & Francis 01.12.2023
Taylor & Francis Ltd
Taylor & Francis Group
Témata:
ISSN:0886-022X, 1525-6049, 1525-6049
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Immune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study, we aimed to evaluate the relationship between a novel comprehensive biomarker, the pan-immune-inflammation value (PIV), and the prognosis of patients undergoing PD. We retrospectively analyzed data from a multicenter, large-sample PD database. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count. The prognostic endpoints in this study were all-cause death all-cause, cardiovascular disease (CVD) and infection-related death. The Kaplan-Meier method, a Cox proportional hazards regression, Fine-Gray competing risk model, smooth curve, and subgroup analysis were used to analyze the independent relationship between PIV and the prognosis of patients undergoing PD. A total of 2796 cases of PD were included, and the study population was divided into Tertiles 1, 2, and 3, according to the tertiles of baseline PIVs. After adjusting for multiple model factors, patients in the Tertile 3 group had a significantly higher risk of all-cause death, CVD death and infection-related death compared with patients with PIV in the Tertile 1 group. Interaction tests showed no positive correlations for subgroup parameters. Regarding all-cause death, compared with the lowest tertile, the multivariable-adjusted hazard ratios (95% confidence intervals) of the highest and middle tertiles were 1.55 (1.25-1.94) and 1.77 (1.43-2.19), respectively; PIV (log2 processing) was associated with 17% excess of mortality in the continuous model. A high PIV at baseline was significantly associated with an increased risk of deaths due to all-causes, CVD and infection in patients undergoing PD.
AbstractList Background Immune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study, we aimed to evaluate the relationship between a novel comprehensive biomarker, the pan-immune-inflammation value (PIV), and the prognosis of patients undergoing PD.Methods We retrospectively analyzed data from a multicenter, large-sample PD database. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count. The prognostic endpoints in this study were all-cause death all-cause, cardiovascular disease (CVD) and infection-related death. The Kaplan–Meier method, a Cox proportional hazards regression, Fine–Gray competing risk model, smooth curve, and subgroup analysis were used to analyze the independent relationship between PIV and the prognosis of patients undergoing PD.Results A total of 2796 cases of PD were included, and the study population was divided into Tertiles 1, 2, and 3, according to the tertiles of baseline PIVs. After adjusting for multiple model factors, patients in the Tertile 3 group had a significantly higher risk of all-cause death, CVD death and infection-related death compared with patients with PIV in the Tertile 1 group. Interaction tests showed no positive correlations for subgroup parameters. Regarding all-cause death, compared with the lowest tertile, the multivariable-adjusted hazard ratios (95% confidence intervals) of the highest and middle tertiles were 1.55 (1.25–1.94) and 1.77 (1.43–2.19), respectively; PIV (log2 processing) was associated with 17% excess of mortality in the continuous model.Conclusions A high PIV at baseline was significantly associated with an increased risk of deaths due to all-causes, CVD and infection in patients undergoing PD.
Immune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study, we aimed to evaluate the relationship between a novel comprehensive biomarker, the pan-immune-inflammation value (PIV), and the prognosis of patients undergoing PD.BACKGROUNDImmune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study, we aimed to evaluate the relationship between a novel comprehensive biomarker, the pan-immune-inflammation value (PIV), and the prognosis of patients undergoing PD.We retrospectively analyzed data from a multicenter, large-sample PD database. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count. The prognostic endpoints in this study were all-cause death all-cause, cardiovascular disease (CVD) and infection-related death. The Kaplan-Meier method, a Cox proportional hazards regression, Fine-Gray competing risk model, smooth curve, and subgroup analysis were used to analyze the independent relationship between PIV and the prognosis of patients undergoing PD.METHODSWe retrospectively analyzed data from a multicenter, large-sample PD database. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count. The prognostic endpoints in this study were all-cause death all-cause, cardiovascular disease (CVD) and infection-related death. The Kaplan-Meier method, a Cox proportional hazards regression, Fine-Gray competing risk model, smooth curve, and subgroup analysis were used to analyze the independent relationship between PIV and the prognosis of patients undergoing PD.A total of 2796 cases of PD were included, and the study population was divided into Tertiles 1, 2, and 3, according to the tertiles of baseline PIVs. After adjusting for multiple model factors, patients in the Tertile 3 group had a significantly higher risk of all-cause death, CVD death and infection-related death compared with patients with PIV in the Tertile 1 group. Interaction tests showed no positive correlations for subgroup parameters. Regarding all-cause death, compared with the lowest tertile, the multivariable-adjusted hazard ratios (95% confidence intervals) of the highest and middle tertiles were 1.55 (1.25-1.94) and 1.77 (1.43-2.19), respectively; PIV (log2 processing) was associated with 17% excess of mortality in the continuous model.RESULTSA total of 2796 cases of PD were included, and the study population was divided into Tertiles 1, 2, and 3, according to the tertiles of baseline PIVs. After adjusting for multiple model factors, patients in the Tertile 3 group had a significantly higher risk of all-cause death, CVD death and infection-related death compared with patients with PIV in the Tertile 1 group. Interaction tests showed no positive correlations for subgroup parameters. Regarding all-cause death, compared with the lowest tertile, the multivariable-adjusted hazard ratios (95% confidence intervals) of the highest and middle tertiles were 1.55 (1.25-1.94) and 1.77 (1.43-2.19), respectively; PIV (log2 processing) was associated with 17% excess of mortality in the continuous model.A high PIV at baseline was significantly associated with an increased risk of deaths due to all-causes, CVD and infection in patients undergoing PD.CONCLUSIONSA high PIV at baseline was significantly associated with an increased risk of deaths due to all-causes, CVD and infection in patients undergoing PD.
Immune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study, we aimed to evaluate the relationship between a novel comprehensive biomarker, the pan-immune-inflammation value (PIV), and the prognosis of patients undergoing PD. We retrospectively analyzed data from a multicenter, large-sample PD database. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count. The prognostic endpoints in this study were all-cause death all-cause, cardiovascular disease (CVD) and infection-related death. The Kaplan-Meier method, a Cox proportional hazards regression, Fine-Gray competing risk model, smooth curve, and subgroup analysis were used to analyze the independent relationship between PIV and the prognosis of patients undergoing PD. A total of 2796 cases of PD were included, and the study population was divided into Tertiles 1, 2, and 3, according to the tertiles of baseline PIVs. After adjusting for multiple model factors, patients in the Tertile 3 group had a significantly higher risk of all-cause death, CVD death and infection-related death compared with patients with PIV in the Tertile 1 group. Interaction tests showed no positive correlations for subgroup parameters. Regarding all-cause death, compared with the lowest tertile, the multivariable-adjusted hazard ratios (95% confidence intervals) of the highest and middle tertiles were 1.55 (1.25-1.94) and 1.77 (1.43-2.19), respectively; PIV (log2 processing) was associated with 17% excess of mortality in the continuous model. A high PIV at baseline was significantly associated with an increased risk of deaths due to all-causes, CVD and infection in patients undergoing PD.
BackgroundImmune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study, we aimed to evaluate the relationship between a novel comprehensive biomarker, the pan-immune-inflammation value (PIV), and the prognosis of patients undergoing PD.MethodsWe retrospectively analyzed data from a multicenter, large-sample PD database. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count. The prognostic endpoints in this study were all-cause death all-cause, cardiovascular disease (CVD) and infection-related death. The Kaplan–Meier method, a Cox proportional hazards regression, Fine–Gray competing risk model, smooth curve, and subgroup analysis were used to analyze the independent relationship between PIV and the prognosis of patients undergoing PD.ResultsA total of 2796 cases of PD were included, and the study population was divided into Tertiles 1, 2, and 3, according to the tertiles of baseline PIVs. After adjusting for multiple model factors, patients in the Tertile 3 group had a significantly higher risk of all-cause death, CVD death and infection-related death compared with patients with PIV in the Tertile 1 group. Interaction tests showed no positive correlations for subgroup parameters. Regarding all-cause death, compared with the lowest tertile, the multivariable-adjusted hazard ratios (95% confidence intervals) of the highest and middle tertiles were 1.55 (1.25–1.94) and 1.77 (1.43–2.19), respectively; PIV (log2 processing) was associated with 17% excess of mortality in the continuous model.ConclusionsA high PIV at baseline was significantly associated with an increased risk of deaths due to all-causes, CVD and infection in patients undergoing PD.
Author Li, Luohua
Wu, Xianfeng
Peng, Fenfen
Feng, Xiaoran
Zhou, Qian
Wen, Yueqiang
Wang, Xiaoyang
Zhan, Xiaojiang
Zhang, Fengping
Author_xml – sequence: 1
  givenname: Fengping
  surname: Zhang
  fullname: Zhang, Fengping
  organization: Department of Nephrology, Jiujiang No. 1 People's Hospital
– sequence: 2
  givenname: Luohua
  surname: Li
  fullname: Li, Luohua
  organization: Department of Nephrology, Jiujiang No. 1 People's Hospital
– sequence: 3
  givenname: Xianfeng
  surname: Wu
  fullname: Wu, Xianfeng
  organization: Department of Nephrology, Affiliated Sixth People's Hospital
– sequence: 4
  givenname: Yueqiang
  surname: Wen
  fullname: Wen, Yueqiang
  organization: Department of Nephrology, The Second Affiliated Hospital of Guangzhou Medical University
– sequence: 5
  givenname: Xiaojiang
  surname: Zhan
  fullname: Zhan, Xiaojiang
  organization: Department of Nephrology, The First Affiliated Hospital of Nanchang University
– sequence: 6
  givenname: Fenfen
  surname: Peng
  fullname: Peng, Fenfen
  organization: Department of Nephrology, Zhujiang Hospital of Southern Medical University
– sequence: 7
  givenname: Xiaoyang
  surname: Wang
  fullname: Wang, Xiaoyang
  organization: Department of Nephrology, The First Affiliated Hospital of Zhengzhou University
– sequence: 8
  givenname: Qian
  surname: Zhou
  fullname: Zhou, Qian
  organization: Department of Medical Statistics, Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University
– sequence: 9
  givenname: Xiaoran
  surname: Feng
  fullname: Feng, Xiaoran
  organization: Department of Nephrology, Jiujiang No. 1 People's Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36632816$$D View this record in MEDLINE/PubMed
BookMark eNqFUl1rFDEUDVKx2-pPUAZ88WXWJDPJJAhSKX4UCvqg4Fu4m0m2WTLJmMy07L83290V2wd9SSD3nHPPzT1n6CTEYBB6SfCSYIHfYiE4pvTnkpZzSQkTBDdP0IIwymqOW3mCFjtMvQOdorOcNxgXVEefodOG84YKwhdo8w1C7YZhDqZ2wXoYBphcDNUt-NlULleQc9QOJtNXd266qcYYUzWmuA4xl7IL1VgYJky5mkNv0jq6sK5Gk9xUHIOvegd-W6DP0VMLPpsXh_sc_fj08fvll_r66-eryw_XtWacTjUjK6sp5cC05BSLticr2nKOCV8BpoZLbaRmjcTMaIqbjgApU9meAbXS6OYcXe11-wgbNSY3QNqqCE7dP8S0VpAmp71RxBY9y2QnV23bciuo7XjpLJpGMNKKovV-rzXOq8H0uoyZwD8QfVgJ7kat462SorC5LAJvDgIp_ppNntTgsjbeQzBxzop2nOGOyrYp0NePoJs4p1C-SlHRkeIH452jV387-mPluNICeLcH6BRzTsYq7ab7nRaDziuC1S5A6hggtQuQOgSosNkj9rHB_3gXe14JUUwD3MXkezXB1sdkEwTtsmr-LfEbKQ_dTw
CitedBy_id crossref_primary_10_1016_j_cyto_2025_156965
crossref_primary_10_1186_s12876_024_03584_2
crossref_primary_10_1007_s10792_025_03733_w
crossref_primary_10_1111_1744_9987_70010
crossref_primary_10_3389_fimmu_2024_1370516
crossref_primary_10_1080_0886022X_2023_2224893
crossref_primary_10_1097_MD_0000000000044460
crossref_primary_10_15829_1728_8800_2025_4417
crossref_primary_10_3390_diagnostics15131617
crossref_primary_10_1038_s41390_023_02769_x
crossref_primary_10_1038_s41598_025_96320_z
crossref_primary_10_1186_s12876_025_04064_x
crossref_primary_10_1111_jch_14944
crossref_primary_10_1186_s13578_024_01226_4
crossref_primary_10_1007_s11255_024_04203_5
crossref_primary_10_1186_s12872_024_04329_5
crossref_primary_10_1016_j_ijcard_2023_131631
crossref_primary_10_1186_s12879_023_08963_w
crossref_primary_10_32596_jucvm_galenos_2025_2025_1_129
crossref_primary_10_1007_s40520_023_02457_0
crossref_primary_10_3390_jcdd11110337
crossref_primary_10_1097_MD_0000000000039643
crossref_primary_10_1007_s12012_024_09855_4
crossref_primary_10_1371_journal_pone_0312877
crossref_primary_10_1097_MD_0000000000040724
crossref_primary_10_1080_0886022X_2023_2294149
Cites_doi 10.1007/s00432-022-03929-y
10.1002/jcla.22228
10.3390/toxins12050340
10.1053/j.jrn.2011.10.020
10.3390/toxins13010070
10.55563/clinexprheumatol/m46d0v
10.1038/nrneph.2013.44
10.3390/cancers14112675
10.2174/18756212MTA3yNzEe1
10.3389/fonc.2022.830138
10.1016/j.semnephrol.2016.10.007
10.1038/nrneph.2016.181
10.1155/2020/9852507
10.1111/jdv.18175
10.1159/000170143
10.1007/s11523-021-00819-0
10.1038/s41416-020-0894-7
10.1186/s12882-016-0394-4
10.1111/j.1440-1797.2006.00541.x
10.1038/s41598-022-10884-8
10.1016/j.tranon.2021.101338
10.1080/0886022X.2022.2100262
ContentType Journal Article
Copyright 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023
2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023 The Author(s)
Copyright_xml – notice: 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023
– notice: 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023 The Author(s)
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.1080/0886022X.2022.2158103
DatabaseName Taylor & Francis Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Research Library
Research Library (Corporate)
Proquest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
– sequence: 4
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate F. Zhang et al
EISSN 1525-6049
ExternalDocumentID oai_doaj_org_article_1f2e6f5979b4446f82f766a583385148
PMC9848369
36632816
10_1080_0886022X_2022_2158103
2158103
Genre Research Article
Multicenter Study
Journal Article
GroupedDBID ---
00X
0YH
123
29P
36B
4.4
53G
5RE
7X7
88E
8FI
8FJ
8G5
ABDBF
ABUWG
ACGEJ
ACGFS
ACUHS
ADBBV
ADCVX
ADRBQ
ADXPE
AENEX
AFKRA
AFKVX
AJWEG
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AQTUD
ARJSQ
AZQEC
BABNJ
BCNDV
BENPR
BLEHA
CCPQU
CS3
DWQXO
EAP
EBC
EBD
EBS
EMB
EMK
EMOBN
EPL
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
H13
HMCUK
HZ~
M1P
M2O
M4Z
O9-
P2P
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PROAC
PSQYO
RPM
SV3
TDBHL
TFDNU
TFL
TFW
TUS
UKHRP
V1S
~1N
AAYXX
AFFHD
CITATION
.GJ
5VS
AALIY
AAORF
AAPXX
ABWCV
AFLEI
AJVHN
AWYRJ
BPHCQ
BRMBE
CAG
CGR
COF
CUY
CVF
CYYVM
CZDIS
DRXRE
DWTOO
ECM
EIF
EJD
HYE
JENTW
M44
NPM
NUSFT
PQQKQ
QQXMO
ZGI
ZXP
3V.
7T5
7XB
8FK
H94
K9.
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c562t-51bfc226a5c962084d1b2466016ba02e69ce9c53905ec20371a1872fd5a2f9ec3
IEDL.DBID DOA
ISICitedReferencesCount 27
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000911466900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0886-022X
1525-6049
IngestDate Fri Oct 03 12:50:31 EDT 2025
Tue Nov 04 02:06:45 EST 2025
Fri Sep 05 13:11:07 EDT 2025
Tue Oct 07 06:46:58 EDT 2025
Mon Jul 21 06:06:11 EDT 2025
Sat Nov 29 07:57:54 EST 2025
Tue Nov 18 21:52:34 EST 2025
Mon Oct 20 23:46:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords biomarker
prognosis
Peritoneal dialysis
pan-immune-inflammation value
Language English
License open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c562t-51bfc226a5c962084d1b2466016ba02e69ce9c53905ec20371a1872fd5a2f9ec3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
OpenAccessLink https://doaj.org/article/1f2e6f5979b4446f82f766a583385148
PMID 36632816
PQID 2871514008
PQPubID 3933335
ParticipantIDs crossref_citationtrail_10_1080_0886022X_2022_2158103
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9848369
proquest_journals_2871514008
pubmed_primary_36632816
crossref_primary_10_1080_0886022X_2022_2158103
informaworld_taylorfrancis_310_1080_0886022X_2022_2158103
doaj_primary_oai_doaj_org_article_1f2e6f5979b4446f82f766a583385148
proquest_miscellaneous_2765072943
PublicationCentury 2000
PublicationDate 2023-Dec
PublicationDateYYYYMMDD 2023-12-01
PublicationDate_xml – month: 12
  year: 2023
  text: 2023-Dec
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
PublicationTitle Renal failure
PublicationTitleAlternate Ren Fail
PublicationYear 2023
Publisher Taylor & Francis
Taylor & Francis Ltd
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Ltd
– name: Taylor & Francis Group
References Ran Y (e_1_3_7_8_1) 2021; 101
e_1_3_7_21_1
e_1_3_7_20_1
e_1_3_7_23_1
e_1_3_7_22_1
e_1_3_7_25_1
e_1_3_7_26_1
Liu S (e_1_3_7_6_1) 2021; 15
Luo H (e_1_3_7_24_1) 2019
e_1_3_7_10_1
e_1_3_7_11_1
e_1_3_7_12_1
e_1_3_7_13_1
e_1_3_7_14_1
e_1_3_7_15_1
e_1_3_7_16_1
e_1_3_7_17_1
e_1_3_7_18_1
e_1_3_7_19_1
e_1_3_7_3_1
e_1_3_7_2_1
e_1_3_7_5_1
e_1_3_7_4_1
e_1_3_7_7_1
e_1_3_7_9_1
References_xml – ident: e_1_3_7_17_1
  doi: 10.1007/s00432-022-03929-y
– ident: e_1_3_7_25_1
  doi: 10.1002/jcla.22228
– ident: e_1_3_7_19_1
  doi: 10.3390/toxins12050340
– ident: e_1_3_7_20_1
  doi: 10.1053/j.jrn.2011.10.020
– volume: 15
  start-page: 206
  issue: 3
  year: 2021
  ident: e_1_3_7_6_1
  article-title: Platelet-to-Lymphocyte ratio is associated with the mortality in peritoneal dialysis patients
  publication-title: Iran J Kidney Dis
– ident: e_1_3_7_4_1
  doi: 10.3390/toxins13010070
– ident: e_1_3_7_14_1
  doi: 10.55563/clinexprheumatol/m46d0v
– ident: e_1_3_7_22_1
  doi: 10.1038/nrneph.2013.44
– ident: e_1_3_7_16_1
  doi: 10.3390/cancers14112675
– ident: e_1_3_7_23_1
  doi: 10.2174/18756212MTA3yNzEe1
– ident: e_1_3_7_12_1
  doi: 10.3389/fonc.2022.830138
– ident: e_1_3_7_3_1
  doi: 10.1016/j.semnephrol.2016.10.007
– volume: 101
  start-page: 2223
  issue: 28
  year: 2021
  ident: e_1_3_7_8_1
  article-title: Association of systemic immune-inflammation index with protein-energy wasting and prognosis in patients on maintenance hemodialysis
  publication-title: Zhonghua Yi Xue Za Zhi
– ident: e_1_3_7_2_1
  doi: 10.1038/nrneph.2016.181
– ident: e_1_3_7_7_1
  doi: 10.1155/2020/9852507
– ident: e_1_3_7_15_1
  doi: 10.1111/jdv.18175
– ident: e_1_3_7_21_1
  doi: 10.1159/000170143
– ident: e_1_3_7_11_1
  doi: 10.1007/s11523-021-00819-0
– start-page: 65:3
  year: 2019
  ident: e_1_3_7_24_1
  article-title: Normal reference intervals of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and systemic immune inflammation index in healthy adults: a large multi-center study from Western China
  publication-title: Clin Lab
– ident: e_1_3_7_9_1
  doi: 10.1038/s41416-020-0894-7
– ident: e_1_3_7_5_1
  doi: 10.1186/s12882-016-0394-4
– ident: e_1_3_7_18_1
  doi: 10.1111/j.1440-1797.2006.00541.x
– ident: e_1_3_7_10_1
  doi: 10.1038/s41598-022-10884-8
– ident: e_1_3_7_13_1
  doi: 10.1016/j.tranon.2021.101338
– ident: e_1_3_7_26_1
  doi: 10.1080/0886022X.2022.2100262
SSID ssj0015872
Score 2.476973
Snippet Immune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study, we aimed...
BackgroundImmune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this study,...
Background Immune-inflammatory biomarkers (IIBs) have been shown to be correlated with prognosis in patients undergoing peritoneal dialysis (PD). In this...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2158103
SubjectTerms biomarker
Biomarkers
Cardiovascular diseases
Cardiovascular Diseases - etiology
Cell number
Clinical Study
Death
Humans
Infections
Inflammation
Leukocytes (neutrophilic)
Lymphocytes
Monocytes
pan-immune-inflammation value
Peritoneal Dialysis
Peritoneum
Population studies
Prognosis
Proportional Hazards Models
Retrospective Studies
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BFiEulHcDBRmJa8racbL2CdGqVS-sVgikvVmJY5cglCzJtr-fmcQJ3QrRQ69xHp7M2PPwzDcAH9BnSD13FP8SWSyTuY0L9MFi4ZXNdeqkF0OzicVyqdZrvQoBty6kVY57Yr9Rl42lGPlHsuxRuaPK-rT5HVPXKDpdDS007sMeIZXJGewdny5XX6dzhFT17ZtwKVGqrViPNTyErq2o_ZJYo48oxBFqPsXHzllBO_Ug_jcgTP9liN7Mp7ymoM7270raE3gcTFP2eZClp3DP1c_g4Zdw-P4cfq7yOq6onsTFOFkUpaHskRFguGNVx_LAa1cyiu-yTdO0jDLA6qbD4apmAca1Y1S71l40qDgZYS0TJDh-m6pYCCLlBXw_O_12ch6HVg2xRQNqG6e88BYtuTy1OhNzJUteCJkR1kuRz4XLtHXapomep84KggnMObLGl2kuvHY2eQmzGr90AAy3UF0SrJ4o0XdNfZE46bRAXWstd7yMQI4sMjbgmFM7jV-Gj3CngbOGOGsCZyM4mh7bDEAetz1wTPyfbiYc7v5C016YsKwN90ibR6dMFxIda6-EX2T4FxR6_shSFYG-Lj1m24dh_NAzxSS3TOBwFBcTNpbO_JWVCN5Pw7gl0DlPXrvmEu9ZoNmNTpPEV7waJHOiIkELUyieRbDYkdkdMndH6upHDzuulVRJpl__f1pv4BESkQwZP4cw27aX7i08sFfbqmvfhfX5B7JEPqs
  priority: 102
  providerName: ProQuest
– databaseName: Taylor & Francis Open Access
  dbid: 0YH
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQixAXWr5TCjISV5fYsbP2ERBVL1Q9gLScLMexS1CVVMmW39-ZxIm6FagHetx17GTssWeePX5DyAfADCrygPtfomSyyD2rAIMxEbV3RgUZxZRsYnV6qtdrc5aiCYcUVokYOk5EEeNajZPbVcMcEfcRJkYJpmcN6E6II7BZmiPf564AaIJRXfnPk-UgQekxfxNWYVhnvsTzr2a2zNPI4n-Lw_RvnujtgMobFup47x5k2ydPkntKP0369JQ8CO0z8uhbOoB_Tn6fuZY1eKckMPheUKfp6iNF0vBAm4G6NN6hprjHSy-7rqcYBdZ2AxQ3LU1UrgPF-2v9eQfGkyLfMtKCw7vxJgvSpLwgP46_fv9ywlK6BubBidowxavowZtzyptS5FrWvBKyRL6XyuUilMYH41VhchW8QKpAx2F0Yq2ciCb44iXZaeFNrwmFZdTUSK0nasCvKlZFkMEIsLfe88DrjMh5lKxPXOaYUuPC8pnyNPWjxX60qR8zcrRUu5zIPO6q8BlVYHkYubjHP7r-3KapbXkE2SIAM1NJANdRi7gqoRc0oH9wR3VGzE0FsptxKyZOeVNscccHHM7aZtPiMlgEudAweG8Zeb8Uw7KAZz2uDd0VPLMC1xuAk4QmXk3KuUhRgJcpNC8zstpS2y0xt0va5tdIPW601EVpDv5DpDfkMfwsppCgQ7Kz6a_CW_LQ_9k0Q_9unL3Xd3s_4Q
  priority: 102
  providerName: Taylor & Francis
Title Pan-immune-inflammation value is associated with poor prognosis in patients undergoing peritoneal dialysis
URI https://www.tandfonline.com/doi/abs/10.1080/0886022X.2022.2158103
https://www.ncbi.nlm.nih.gov/pubmed/36632816
https://www.proquest.com/docview/2871514008
https://www.proquest.com/docview/2765072943
https://pubmed.ncbi.nlm.nih.gov/PMC9848369
https://doaj.org/article/1f2e6f5979b4446f82f766a583385148
Volume 45
WOSCitedRecordID wos000911466900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: DOA
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: 7X7
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: BENPR
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: PIMPY
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: M2O
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVAWR
  databaseName: Taylor & Francis Online Journals
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: TFW
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
– providerCode: PRVAWR
  databaseName: Taylor & Francis Open Access
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: 0YH
  dateStart: 19870101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgILQXxDeBURmJ14zacRL7kaFV46ElQkNkT1bi2BCEkqnp9vdzFztVOyH1hRdLjZO4vjvn7uy73xHyAXyG1DGL-188i0UyN3ENPljMnTSVSq1w3BebyFcrWZaq2Cn1hTFhHh7YE-4jc9xmDsxeVQtwXZzkLs-yCpOFwFgQY5ovWD2TMxXOD1I5lm2CJYQhtryccncQVVti2SVegm_I-SloPMmmillBK43g_XegS_9lgN6No9xRTIsn5HGwKOknP5On5J7tnpFHy3Bm_pz8LqoubjENxMYwFkiAz1akiPNtaTvQKrDINhS3Zel1368pBm51_QDdbUcD-upAMeVs_bMHfUcRIhmRvGFsTD5BZJMX5Pvi_PLzRRwqLMQG7J5NnLLaGTDAqtSoDMgoGlZzkSFES13NgfDKWGXSRM1Tazii-1UMKOuatOJOWZO8JEcdjPSaUPjyqQbR8HgDLmfq6sQKqzioSGOYZU1ExERhbQL8OFbB-KPZhFIaGKORMTowJiKn28euPf7GoQfOkH3bmxE-e7wAQqWDUOlDQhURtct8vRl3T5wvdaKTA3_gZJIUHb4Hg0a_FF4MBldE3m-7YSXj8UzV2f4G7snBWgZfR8ArXnnB2s4iAcOQS5ZFJN8Tub1p7vd07a8RLVxJIZNMvfkfdHlLjmGqiQ_nOSFHm_WNfUcemttNO6xn5P786gLavMzHVs7Ig7PzVfFtNi5OaJf8K1wrviyLK_h1ufjxF-MGNd0
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFAEX3g9DgUWCo0u8Xju7B4R4VY3aRDkUKZy29nq3TYXsEKcg_hS_kRl7HZoK0VMPXLN-7eab1-7MNwAvMWZIXGRp_4unoYj7JswxBgu5kyZTiRWOt80mBuOxnE7VZAN-dbUwlFbZ6cRGUReVoT3y1-TZo3FHk_V2_i2krlF0utq10GhhsWd__sCQrX4z_Ij_7yvOdz4dfNgNfVeB0KCtX4ZJlDuDTkeWGJXyvhRFlHOREi1JnvW5TZWxyiSx6ifWcGK0yyI54K5IMu6UNTE-9wpsCgS77MHmZDiafFmdWySyaReFokupvXza1QwRm7ekdk98ijEp59toaWXUdery1rBpGnCOMvVvju_5_M0zBnHn1v-2lLfhpne92btWVu7Ahi3vwrWRTy64ByeTrAxnVC9jQ1wcFJW2rJMRIbpls5plHsu2YLR_zeZVtWCU4VZWNQ7PSuZpamtGtXmLowodA0Zc0kR5ju-mKh2igLkPny9lpg-gV-KbHgFDE6EKog3kBcbmictjK6zi6EsYE9moCEB0kNDG87RTu5CvOuroXD2SNCFJeyQFsL26bd4SlVx0w3vC2-pi4hlvfqgWR9qrLR05nJvDoFPlQojUSe4GKa6CjGN01YUMQJ1Fq14220yu7Qmj4ws-YKuDp_aKs9Z_sBnAi9Uwqjw6x8pKW53iNQMMKzAoFPiIh60krGYRowfNZZQGMFiTkbVpro-Us-OGVl1JIeNUPf73Zz2H67sHo329PxzvPYEbOKG4zW7agt5ycWqfwlXzfTmrF8-8bmBweNky9BvC_Zot
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQiyoutHwHChiJq8vasbP2ESgrELDaQxF7sxLHboNQskq2_H5mEifqVqAe4BrHTsYee-bZ4zeEvAbMoAL3uP8lMibTmWMFYDAmgna5UV4GMSSbmC-Xer02qxhN2MWwSsTQYSCK6NdqnNybMowRcW9gYmRgetaA7oQ4AZulOfJ97vfkWKDSZ4vv00GC0n3-JqzCsM54iedvzeyYp57F_xqH6Z880esBlVcs1OLwP8h2RO5G95S-HfTpHrnl6_vk4Gs8gH9AfqzymlV4p8Qz-F9Qp-HqI0XScE-rjuZxvH1JcY-XbpqmpRgFVjcdFFc1jVSuHcX7a-15A8aTIt8y0oLDt_EmC9KkPCTfFh_O3n9kMV0Dc-BEbZniRXDgzeXKmUzMtCx5IWSGo1LkM-Ez47xxKjUz5Z1AqsCcw-iEUuUiGO_SR2Svhi89IRSWUVMitZ4oAb-qUKReeiPA3jrHPS8TIsdRsi5ymWNKjZ-Wj5SnsR8t9qON_ZiQk6naZiDzuKnCO1SB6WXk4u4fNO25jVPb8gCyBQBmppAAroMWYZ5BL2hA_-CO6oSYqwpkt_1WTBjyptj0hh84HrXNxsWlswhyoWHw3hLyaiqGZQHPevLaN5fwzhxcbwBOEpp4PCjnJEUKXqbQPEvIfEdtd8TcLamri5563Gip08w8_QeRXpKD1enCfvm0_PyM3IGSdIgOOiZ72_bSPye33a9t1bUv-on8G8BNQq8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pan-immune-inflammation+value+is+associated+with+poor+prognosis+in+patients+undergoing+peritoneal+dialysis&rft.jtitle=Renal+failure&rft.au=Fengping+Zhang&rft.au=Luohua+Li&rft.au=Xianfeng+Wu&rft.au=Yueqiang+Wen&rft.date=2023-12-01&rft.pub=Taylor+%26+Francis+Group&rft.issn=0886-022X&rft.eissn=1525-6049&rft.volume=45&rft.issue=1&rft_id=info:doi/10.1080%2F0886022X.2022.2158103&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1f2e6f5979b4446f82f766a583385148
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0886-022X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0886-022X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0886-022X&client=summon